Additional Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
|ClinicalTrials.gov Identifier: NCT01671683|
Recruitment Status : Completed
First Posted : August 23, 2012
Last Update Posted : August 23, 2012
|Condition or disease|
Neoadjuvant chemoradiotherapy (NCRT) has been used as standard treatment modality in patients with locally advanced rectal cancer (LARC) because of increased local control, enhanced sphincter preservation, and less toxicity.NCRT has enhanced down-staging of tumor and reduced local recurrence. However, survival benefit of NCRT has not been demonstrated and the rate of distant metastasis was still reported as high as 30%.
Patients with pathologic complete remission (pCR) after NCRT have shown excellent survival benefit. We inferred that additional chemotherapy during the resting period could enhance the pCR rate. The aim of the present study is to evaluate the safety and efficacy of an additional 4-week chemotherapy with capecitabine after the conventional 6-week NCRT in patients with LARC.
|Study Type :||Observational|
|Actual Enrollment :||44 participants|
|Official Title:||A Phase II Study of Additional Four-week Chemotherapy With Capecitabine During the Resting Periods After Six-week Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer|
|Study Start Date :||July 2010|
|Actual Study Completion Date :||September 2011|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01671683
|Korea, Republic of|
|Chungnam National University Hospital|
|Daejeon, Korea, Republic of, 301-721|
|Principal Investigator:||Ji Yeon Kim, MD., PhD||Surgical Oncology Research Lab|